Table 4.
Characteristics of patients with NCFB with and without P. aeruginosa eradication in the 3, 6, 9 and 12 months follow-up.a,b
| Eradication | 3 months | 6 months | 9 months | 12 months | ||||
|---|---|---|---|---|---|---|---|---|
| Yes (n = 41) | No (n = 26) | Yes (n = 34) | No (n = 33) | Yes (n = 29) | No (n = 38) | Yes (n = 27) | No (n = 40) | |
| Age (years) | 65.9 ± 14.8 | 69.3 ± 14.0 | 64.5 ± 15.6 | 70.1 ± 13.0 | 63.7 ± 16.3 | 69.9 ± 12.6 | 64.4 ± 16.4 | 69.1 ± 13.1 |
| Sex, males, n (%) | 24 (58.5) | 16 (61.5) | 19 (55.9) | 21 (63.6) | 16 (55.2) | 24 (63.2) | 15 (55.6) | 25 (62.5) |
| Ex/active smokers, n (%) | 19 (46.3) | 11 (42.3) | 15 (44.1) | 15 (45.5) | 12 (41.4) | 18 (47.4) | 11 (40.7) | 19 (47.5) |
| First P. aeruginosa culture, n (%) | 11 (26.8) | 8 (30.7) | 10 (52.6) | 9 (47.4) | 9 (47.4) | 10 (52.6) | 9 (47.4) | 10 (52.6) |
| Concomitant azithromycin, n (%) | 27 (65.9) | 19 (73.1) | 23 (67.6) | 23 (69.7) | 18 (62.1) | 28 (73.7)c | 16 (59.3) | 30 (75) |
| Oral ciprofloxacin | 26 (63.4) | 16 (61.5) | 22 (64.7) | 20 (60.6) | 19 (65.5) | 23 (60.5) | 17 (63.0) | 25 (62.5) |
| P. aeruginosa mucoid | 18 (43.9) | 22 (84.6)d | 14 (41.2) | 26 (78.8)c | 10 (65.5) | 30 (78.9)d | 8 (70.4) | 32 (80)d |
| Mean FVC post-BD, % predicted | 80.4 ± 21.5 | 78.3 ± 19.2 | 80.2 ± 23.1 | 79.1 ± 17.9 | 80.3 ± 20.8 | 79.1 ± 20.4 | 80.1 ± 21.2 | 79.3 ± 20.2 |
| Mean FEV1 post-BD, % predicted | 58.3 ± 26.3 | 56.1 ± 22.5 | 57.5 ± 27.1 | 57.4 ± 22.7 | 57.6 ± 26.7 | 57.3 ± 23.4 | 56.7 ± 27.4 | 58.1 ± 23.1 |
NCFB: non-cystic fibrosis bronchiectasis; FVC post-BD: forced vital capacity post-bronchodilatation (% predicted); FEV1 post-BD: forced expiratory volume in 1 second post-bronchodilatation (% predicted).
a Data are presented as mean ± standard deviation (X ± SD).
b p Values: comparisons between groups were tested using the Pearson’s χ 2 (categorical variables) or Wilcoxon test (non-normally distributed continuous variables after analysing the normality with Kolmogorov–Smirnov test).
c p < 0.1.
d p < 0.001.